[Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial]

Urologe A. 2020 Jun;59(6):723-724. doi: 10.1007/s00120-020-01176-y.

[Article in German]

Author

Gunhild von Amsberg¹

Affiliation

¹ Professur für Uroonkologie der II. Medizinischen Klinik des Onkologischen Zentrums und der Martini-Klinik, Universtitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. [email protected].

PMID: 32240319
DOI: 10.1007/s00120-020-01176-y

No abstract available

MeSH terms

Androgen Antagonists / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Disease-Free Survival
Docetaxel / therapeutic use
Humans
Male
Neoplasm Metastasis
Prostatic Neoplasms* / drug therapy

Substances

Androgen Antagonists
Docetaxel